Igor Fisch New candidate, independent Igor Fisch is a co-founder of Selexis SA, a biotech company based in Switzerland. He grew the company from inception to profits in less than 5 years with up to > 5MCHF in revenues with a net margin > 20%. He has a proven track-record for achieving major licensing deals in the Biotech and Pharmaceutical industry in USA, Europe, Asia and Australia. Igor Fisch has a very strong network among decision makers and entrepreneurs worldwide in the Pharmceutical and Biotech industry. Igor Fisch is also an Experienced Director, proactive manager and able, even in difficult environments, to set-up and motivate teams and to facilitate collaborations around ambitious objectives. He is currently and since 2001 President of the Board of Directors and Chief Executive Officer of Selexis SA, where he was a Co-founder in charge of raising the capital to create a successful biotech company. Igor Fisch is Member of the Board of Directors of Viroblock SA and a Member of the Strategy Council of the Venture Kick Initiative 1
Steven Morrell New candidate, independent Steven Morrell has comprehensive experience in international venture capital investing in life sciences, industrial, materials technology and aquaculture sectors. He also has comprehensive senior leadership experience with highly profitable, multi-national corporations in technology, pharmaceutical and biotech industries in international business environments. Steven Morrell's experience includes full P&L responsibility for budgeting, new product introduction, strategic planning, labor relations, production, sales, marketing, competitive analysis and financial forecasting; consistently selected for special business efforts in new market penetration. He has handson knowledge of mergers, acquisitions, divestitures, technology transfer, product licensing, distribution channels, new business start-ups, process reengineering and various quality initiatives. He also has extensive background in cross-cultural staff supervision throughout Western Europe, Eastern Europe and Russia; fluent in German and Norwegian; familiar with Russian. Steven Morrell is currently employed as Managing Director and Part Owner of Teknoinvest AS, Oslo, Norway and Teknoinvest in New York, USA. He serves as Chairman of the Board of Directors of Marical, Inc. (USA), Low Salinity, Inc. (USA) and Cidra Corporation (USA) as well as a member of the Board of Directors of QuNano AB (Sweden), Glo AB (Sweden) and Sol Voltaic AB (Sweden). 2
Yegor S. Vassetzky New candidate, independent Yegor S. Vassetzky is CNRS research director (DR2), Head of the laboratory of Chromatin, Development and Cancer at the Institut Gustave Roussy in Paris. Previously he was postdoctoral and later research fellow at the Laboratory of Genome Dynamics and Development, Institute of Human Genetics, Montpellier. He has worked as Postdoctoral fellow in the laboratory of Molecular Embryology at the Institut Jacques Monod, Paris, the laboratory of Chromatin Research of the Swiss Institute for Experimental Cancer Research (ISREC), Lausanne, Switzerland and in the laboratory of Professor Klaus Scherrer at the Institut Jacques Monod, Paris. Yegor S. Vassetzky has a B.Sc. from Department of Molecular Biology, State University of Moscow, a Ph.D. from the Institute of Molecular Biology, USSR Academy of Sciences, Moscow, and a Dr. Sci. from the Institute of Developmental Biology, Russian Academy of Sciences, Moscow. Yegor S. Vassetzky holds no directorships. 3
Aleksandr Shuster Chairman of the Board, elected 2010, representing Trans Nova Investments Ltd. owning 53,3% of the shares of Affitech A/S. Chairman of the Board of Directors of: Masterpharm, Lekko and MasterClone (all Russia). Aleksandr Shuster is a leading Russian drug development entrepreneur. He is a biochemist with special competences in Biotechnology, Molecular Biology, and Molecular Immunology. Aleksandr Shuster is co-owner of Trans Nova Investments Ltd. and NauchTekhStroy Plus, a biotechnology company. He founded Lekko as the major shareholder of the Company that developed a range of drugs which were bought by Pharmstandard. Aleksandr Shuster also founded the companies Masterpharm and Masterclone which primarily focus on new and biological drugs. 4
Keith McCullagh Vice Chairman, elected 2009, independent Chairman of the Boards of Directors of: Pharmacy 2U Limited and Xention Limited, (both UK). Keith McCullagh, is an experienced pharmaceutical executive and bioscience entrepreneur. He joined Affitech AS as non-executive chairman in 2008 and was elected Chairman of the Board of Affitech A/S on the combination with Pharmexa in 2009. He moved to the position of Vice Chairman following the investment from Trans Nova Investments Ltd. in 2010. Keith McCullagh was previously CEO of Santaris Pharma, a Danish biopharmaceutical company and has served as Chairman of several other European companies. From 1986 to 1998 he was Chief Executive of British Biotech plc, a company he built into one of Europe s leading biopharmaceutical businesses. Prior to that, Keith was UK Research Director for G.D. Searle & Co, Inc., now part of Pfizer. Keith McCullagh qualified in veterinary medicine from the University of Bristol and has a PhD in pathology from the University of Cambridge, UK. 5
Victor Kharitonin Elected 2010, representing Trans Nova Investments Ltd. owning 53,3% of the shares of Affitech A/S Chairman of the board of Directors of: JSC Pharmstandard (Russia). Victor Kharitonin is one of the leading figures in the Russian medical industry. He is a co-owner of TransNova Investments Limited, which owns shares in Russian and European companies. Victor Kharitonin is furthermore through Augment Investments the major shareholder in Pharmstandard, Russia s largest domestic pharmaceutical company, which owns 50% of the biotech company NauchTekhStroy Plus. 6
Andrei Petrov Elected 2010, representing Trans Nova Investments Ltd. owning 53,3% of the shares of Affitech A/S Andrei Petrov holds no other directorships. Andrei Petrov is a Russian scientist with a vast knowledge and experience within molecular biology, cell biology and immunology. Andrei Petrov graduated from Moscow State University Chemistry Department in 1995. His PhD thesis was devoted to study of structure and function of telomerase which is ribonucleoprotein complex related to the mechanisms of cellular control over proliferation and senescence. He considerably contributed to the basic research on the subject exploring modern and sophisticated molecular biology and biochemistry methods not used in his laboratory before. Andrei Petrov did his post-doctoral training at the French Oncology Center referred as Institut Gustave Roussy (Villejuif, France) joining the group headed by Yegor Vassetzky. Andrei Petrov made a core part of the group to investigate the mechanisms underlying the mysterious type of muscular dystrophy FSHD. During this time (2002-2006) he established a set of important tools for studying the chromatin structure, its epigenetic features and reorganization, transcriptional regulation accounted for development of the pathology. Andrei substantially contributed to the overall performance of the research group at that time. 7